Risk factor
Resilient to price shocks
Profitability factor
Strong growth
About
DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITD
Target Price
The average target price of 086450.KQ is 30000 and suggests 46.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation t